What Coultreon Biopharma does

Coultreon Biopharma is a clinical-stage Belgian biopharmaceutical company founded in 2025 (formerly Onco3R Therapeutics) that develops oral small-molecule therapeutics targeting clinically validated pathways in immunology, autoimmune, metabolic, and oncological diseases. The company's lead asset, COL-5671, is a first-in-class, highly selective oral inhibitor of salt-inducible kinase 3 (SIK3) currently advancing into Phase 2 clinical trials for psoriasis and ulcerative colitis, with proof-of-concept data expected in 2027. COL-5671 was originally developed by Galapagos NV and fully transferred to Coultreon in April 2025 via an exclusive license accompanied by a seed investment. The compound's mechanism — inhibiting SIK3 to simultaneously suppress pro-inflammatory cytokines TNFα, IL-12, and IL-23 while promoting immunoregulatory IL-10 — is positioned as functionally analogous to combining anti-TNFα and anti-IL-23 biologics in a single once-daily oral pill.

Underlying Coultreon's pipeline is a proprietary AI-augmented drug design platform trained on a dataset of over 300,000 compounds, which integrates AI-driven modelling, structure-based design, early safety prediction, and human dose projections with expert medicinal chemistry in a continuous Design-Predict-Make-Test-Analyze cycle. The platform also supports a broader pipeline beyond COL-5671, including undisclosed candidates in immunology and metabolic diseases, plus precision oncology programs targeting FGFR3, SMARCA2, and P53 Y220C with IND-enabling studies expected by mid-2026.

Coultreon's business model is pre-commercial: the company generates no current revenue and is funded entirely by investor capital, having closed a $125 million oversubscribed Series A round in April 2026 led by Sofinnova Investments, Forbion, and Novo Holdings. Future revenue, once COL-5671 or other candidates receive regulatory approval, is expected to derive from product sales distributed through specialty pharmacy and prescription-based channels typical of oral autoimmune therapies. Headquartered in Leuven, Belgium, with 11-50 employees, the company operates a clinical development-focused GTM motion engaging trial sites, academic medical centers, and regulatory bodies across Europe.

Name

Coultreon Biopharma

Legal name

Coultreon Biopharma

Website

https://onco3r.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Coultreon Biopharma is a clinical-stage Belgian biotech developing oral small-molecule therapeutics for autoimmune and inflammatory diseases, with lead asset COL-5671 (SIK3 inhibitor) in Phase 2 for psoriasis and ulcerative colitis. Pre-revenue, funded by a $125M Series A.

Ownership category

akta.pro rank

Product category

Autoimmune Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Gastroenterology Specialty Pharmaceuticals (HLAIACAE), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)

Keywords

• Small molecule therapeutics
• Autoimmune disease drugs
• Oral kinase inhibitors
• Drug discovery platform
• Inflammatory disease treatment

Headquarters

HQ city

Heverlee

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Drug development and commercialization: As a clinical-stage biopharma, Coultreon generates no current revenue. The company's business model centers on developing proprietary drug candidates through clinical trials and commercializing approved therapies. Revenue will derive from product sales of COL-5671 and future pipeline candidates upon regulatory approval. The company is pre-revenue and funded entirely by investor capital.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Coultreon Biopharma is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics for chronic inflammatory, autoimmune, metabolic, and oncology indications. Its lead asset, COL-5671, is a first-in-class highly selective oral SIK3 inhibitor currently advancing through Phase 2 trials for psoriasis and ulcerative colitis, supported by a proprietary AI-augmented drug design platform trained on over 300,000 compounds.

Product overview

Coultreon Biopharma is a clinical-stage Belgian biotech developing oral small molecule therapeutics for chronic inflammatory and autoimmune diseases. The company's lead asset is COL-5671, a first-in-class SIK3 inhibitor currently in Phase 2 trials for psoriasis and ulcerative colitis. The pipeline also includes undisclosed candidates for immunology and metabolic diseases, as well as oncology candidates (bladder cancer, lung cancer, solid tumors). The company leverages a proprietary AI-augmented drug design platform trained on over 300,000 compounds to support its drug discovery and development programs.

Differentiator

Problem solved

Functional benefit

Products and services

• COL-5671 (SIK3 Inhibitor) First-in-class, highly selective oral small-molecule SIK3 inhibitor intended as a once-daily oral treatment for chronic immune-mediated inflammatory diseases, initially psoriasis and ulcerative colitis. It mimics anti-TNFα and anti-IL-23 biologic activity in a single oral pill, simultaneously suppressing TNFα, IL-12, and IL-23 while promoting IL-10 production. Currently being evaluated in Phase 2 clinical trials for adult patients with autoimmune inflammatory conditions.
• Precision Oncology Pipeline Candidates (FGFR3, SMARCA2, P53 Y220C) Preclinical-stage targeted small-molecule oncology candidates designed for patients with cancers driven by FGFR3, SMARCA2, and P53 Y220C alterations, intended for solid tumor indications such as bladder and lung cancer. The program is being progressed through preclinical development with IND-enabling studies expected by mid-2026.

Quantifiable outcome

• Phase 1 first-in-human study demonstrated favourable safety and tolerability profile with highly attractive pharmacokinetic profile including long half-life and low inter-participant variability
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

One partnership is on record.

• Galapagos NVcoreStrategic or Co-development Partner · 1 April 2025Galapagos NV developed COL-5671 and fully transferred the SIK3 inhibitor program to Coultreon in April 2025, including providing an initial seed investment. Galapagos also participated as an investor in the $125M Series A round. This dual relationship involves both an inbound licensing/asset transfer and co-investment.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Galapagos NV: Belgian biopharma that originally developed and transferred COL-5671 to Coultreon and holds an ongoing investor and asset licensor relationship. Operates a broader immunology pipeline (JAK inhibitors, SIK programs) and is a directly comparable Belgian specialty immunology company.
• Eli Lilly: Major biopharma with Taltz (anti-IL-17) and Olumiant (oral JAK) franchises in psoriasis and autoimmune disease. Recently acquired Dice Therapeutics to bolster oral immunology pipeline; a likely strategic acquirer for differentiated oral autoimmune assets.
• AbbVie: Major biopharma with Humira (anti-TNF), Skyrizi (anti-IL-23), and Rinvoq (oral JAK) franchises dominating psoriasis and ulcerative colitis. Establishes efficacy and commercial benchmarks that COL-5671 must clear to gain meaningful market share.
• Bristol Myers Squibb: Major biopharma with Sotyktu (oral TYK2 inhibitor approved for psoriasis) and Zeposia (S1P modulator for UC). Sets the competitive benchmark for oral autoimmune therapies and represents both a competitor and a potential strategic acquirer.
• UCB: Belgian biopharma with Cimzia (anti-TNF), Rystiggo, and other immunology franchises. Directly comparable as a Belgian specialty biopharma with established autoimmune disease commercialization in Europe.
• Pfizer: Major biopharma with oral JAK inhibitors Cibinqo (atopic dermatitis) and Xeljanz (rheumatoid arthritis, UC) competing in the oral autoimmune space. Represents incumbent competition and a likely strategic acquirer for late-stage immunology assets.

Direct peers

• Morphic Medical: Clinical-stage biotech developing oral small-molecule integrin inhibitors for autoimmune diseases including inflammatory bowel disease. Closely comparable as an oral small-molecule immunology developer pursuing autoimmune indications like ulcerative colitis.
• Pliant Therapeutics: Clinical-stage biotech developing oral small-molecule integrin inhibitors (αvβ1, αvβ6) for fibrosis and inflammation-related conditions. Comparable as a clinical-stage small-molecule developer targeting integrin and kinase pathways with a similar capital and clinical profile.
• Argenx: Belgian clinical-stage immunology biotech developing antibody therapeutics for autoimmune diseases (efgartigimod/Vyvgart in myasthenia gravis, ITP, CIDP). Comparable as a Belgium-based immunology-focused biotech with a novel mechanism targeting validated pathways and strong clinical-stage positioning.
• Dice Therapeutics: Clinical-stage biotech (acquired by Eli Lilly in 2023) developing oral IL-17 antagonists for autoimmune diseases including psoriasis. Directly comparable as an oral small-molecule immunology developer competing against injectable biologics in autoimmune indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/coultreon-biopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coultreon Biopharma